Search Patents
  • Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Publication number: 20050004353
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: October 14, 2003
    Publication date: January 6, 2005
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng "Luke" Li, Haichun Huang
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20110045537
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: July 6, 2010
    Publication date: February 24, 2011
    Applicant: AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng "Luke" Li, Haichun Huang
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20140004127
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: August 13, 2013
    Publication date: January 2, 2014
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors
    Publication number: 20120269819
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: May 21, 2012
    Publication date: October 25, 2012
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Luke Li, Haichun Huang
  • HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS
    Publication number: 20080107655
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 8, 2008
    Applicants: Amgen Inc., Medarex, Inc.
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng Li, Haichun Huang
  • Low dose IFN-gamma compositions and their use for treatment of interferon-sensitive diseases
    Publication number: 20040081635
    Abstract: The use of low doses of IFN-gamma in the treatment of interferon-sensitive diseases is described. The IFN-gamma can be administered orally, preferably buccally or sublingually, or parenterally in low doses to activate monocyte, neutrophil, or B cell function, to decrease acute inflammation, or to treat cancer, bacterial or fungal diseases, or fibrosis in a patient suffering from such disease states. Pharmaceutical formulations containing low doses of IFN-gamma in combination with a pharmaceutical acceptable carrier and suitable for oral administration are also described.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Inventors: Joseph M. Cummins, Edward P. Amento
  • Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8202976
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng (Luke) Li, Haichun Huang
  • Recombinant avian interferon-gamma (IFN-.gamma.)
    Patent number: 6083724
    Abstract: A cDNA corresponding to the chicken interferon-.gamma. (IFN-.gamma.) gene has been isolated. The invention thus provides avian IFN-.gamma. polypeptides, nucleic acids encoding them, and their recombinant production. The nucleic acids and polypeptides are useful as therapeutic agents and as adjuvants for the treatment of birds.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: July 4, 2000
    Assignee: Commonwealth Scientific and Industrial Research Organization
    Inventors: John William Lowenthal, Jennifer Joy York, Terri Ellen O'Neil, Stephen Rhodes, Matthew Robert Digby
  • Methods for treating IFN-? mediated diseases using human anti-IFN-? neutralizing antibodies as selective IFN-gamma pathway inhibitors
    Patent number: 8529893
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 10, 2013
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • DISTINCT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A MODULATED INFLAMMATION AND FIBROSIS
    Publication number: 20160096885
    Abstract: Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 7, 2016
    Applicant: Cedars-Sinal Medical Center
    Inventors: David Q. Shih, Stephan R. Targan, Janine Bilsborough
  • Compositions and methods for decreasing IGIF and IFN-.gamma. production by administering an ICE inhibitor
    Patent number: 5985863
    Abstract: The present invention relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma inducing factor (IGIF). The invention also relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma (IFN-.gamma.). The compositions comprise a therapeutically effective amount of a compound which inhibits interleukin-1.beta. converting enzyme (ICE) and a pharmaceutically acceptable carrier. The methods comprise the step of administering the above compositions to a subject. The present invention also relates to methods for treating or reducing the advancement, severity or effects of an IGIF- or IFN-.gamma.-mediated inflammatory, infectious or autoimmune condition.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: November 16, 1999
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Michael Su, Yong Gu, David J. Livingston
  • Use of canine interferon-.gamma.(IFN-.gamma.) to treat non-atopic dermatitis
    Patent number: 5955069
    Abstract: Methods for treating intractable dermatitis in dogs are described. The methods involve the administration by injection of formulations comprising canine interferon-.gamma. and, optionally, other agents. The canine IFN-.gamma. may be produced in recombinant expression systems such as E. coli or B. mori.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: September 21, 1999
    Assignee: Toray Industries, Inc.
    Inventors: Tomiya Uchino, Katsushige Yamada, Fumiyoshi Okano, Masahiro Satoh, Isao Kawakami
  • TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS
    Publication number: 20220177598
    Abstract: In various embodiments targeted interferon constructs are provided. In certain embodiments the constructs comprise a full-length immunoglobulin or a camelid antibody attached to an interferon gamma (IFN?) where said immunoglobulin or camelid antibody is an antibody that binds to a tumor associated antigen; a first interferon gamma (IFN?) is attached to a first constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a first proteolysis resistant peptide linker; a second interferon gamma is attached to a second constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a second proteolysis resistant peptide linker; and the first proteolysis resistant linker and the second proteolysis linker have a length and flexibility that permits said first interferon gamma and said second interferon gamma to dimerize.
    Type: Application
    Filed: January 29, 2020
    Publication date: June 9, 2022
    Inventors: Kham M. Trinh, John Matthew Timmerman, Sherie Leaver Morrison
  • METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
    Publication number: 20130142809
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: November 21, 2012
    Publication date: June 6, 2013
    Inventors: Andrew A. Welcher, Michael J. Boedigheimer, James B. Chung
  • Thermostable variants of human interferon-.gamma.(IFN-.gamma.)
    Patent number: 6046034
    Abstract: The invention provides new variants of recombinant human interferon-.gamma. (rhIFN-.gamma.), vectors and host cells for their production, and therapeutic methods employing them. The variants are characterized by the substitution of one or more pairs of amino acids selected from Glu.sup.8 -Ser.sup.70, Ala.sup.18 -His.sup.112, Lys.sup.81 Leu.sup.121, and Gln.sup.49 -Leu.sup.96 by pairs of Cys residues, and optionally by the deletion of from one to ten amino acid residues from C-terminus of the native IFN-.gamma. sequence. The variants of the invention exhibit greater thermal stability and no loss of biological activity as compared to native-sequence rhIFN-.gamma..
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: April 4, 2000
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E. V.
    Inventors: Gero Waschutza, Volkhart Li, Bernd Otto
  • IFN-gamma as an active substance for inhibiting and preventing degradation processes in bone
    Patent number: 4921697
    Abstract: This invention relates to methods for preventing and treating bone diseases caused by bone loss comprising administering to a patient a pharmaceutical composition with IFN-.gamma. as the active substance.
    Type: Grant
    Filed: May 30, 1986
    Date of Patent: May 1, 1990
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Meinrad Peterlik, Oskar Hoffmann
  • Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) purified from murine liver
    Patent number: 5912324
    Abstract: A protein which induces IFN-.gamma. production by immunocompetent cells and has a molecular weight of 19,000.+-.5,000 daltons on SDS-PAGE or gel filtration and a pI of 4.8.+-.1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: June 15, 1999
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Haruki Okamura, Tadao Tanimoto, Kakuji Torigoe, Toshi Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
  • Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
    Publication number: 20180057603
    Abstract: The present invention provides a fusion proteins comprising (a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-p185her2/neu polypeptide or an anti-EGFR polypeptide; (b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than p185her2/neu or EGFR; and (c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFN?), wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administering i) an anti-p185her2/neu antibody, an anti-EGFR antibody or an erbB kinase inhibitor and interferon-gamma (IFN?); or ii) a fusion protein of the invention.
    Type: Application
    Filed: February 9, 2016
    Publication date: March 1, 2018
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Mark Greene, Hongtao Zhang, Hiromichi Tsuchiya, Yasuhiro Nagai, Lian Lam, Aaron Runkle, Jeffrey Drebin, Mei Qing Ji
  • gamma-IFN liquid-droplet aerosol and method
    Publication number: 20010043906
    Abstract: A liquid-droplet aerosol composition for delivery to a patient's respiratory tract is disclosed. The aerosol is formed by placing an aqueous &ggr;-IFN solution having stabilizing and dispersing components against a plate having defined-size openings, and forcing the solution through the openings under conditions effective to form aqueous droplets having a volume mean diameter in one or more of a number of selected sizes in the 1-10 micron size range. The aerosol has the desired-size droplets and a &ggr;-IFN biological activity and molecular size distribution substantially the same as that of the aqueous &ggr;-IFN solution. Also disclosed is a method of administering to a selected region of a patient's respiratory tract, an amount of human &ggr;-IFN having a known, selected gamma-interferon biological activity and molecular size distribution.
    Type: Application
    Filed: December 22, 2000
    Publication date: November 22, 2001
    Inventors: Peter Van Vlasselaer, J. Woodruff Emlen
  • Recombinant methods of making gamma interferon compositions
    Patent number: 5595888
    Abstract: Provided are methods for the production of mixtures of interferon (IFN)-.gamma. polypeptides. The methods employ a single species of IFN-.sub..gamma. DNA having codons for Met-Gln and for residues 2-143 of the mature human IFN-.sub..gamma. amino acid sequence. Expression of such DNA in a suitable recombinant host cell affords a mixture of polypeptides having N-terminal Met-Gln, H-Gln, or H-pyroglutamate residues and C-termini at Arg.sup.139, Ser.sup.142, or Gln.sup.143 of the mature IFN-.sub..gamma. sequence. The polypeptides so produced exhibit the antiviral and antiproliferative activities as well as the acid lability characteristic of native human IFN-.sub..gamma..
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: January 21, 1997
    Assignee: Genentech, Inc.
    Inventors: Patrick W. Gray, Ernst H. Rinderknecht
Narrow Results

Filter by US Classification